Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered Treatments at Home NEW HAVEN, Conn., Dec. 03, 2025 (GLOBE NEWSWIRE) -- As millions of patients and caregivers continue to struggle with acute agitation episodes associated with bipolar disorder and schizophrenia, a timely and highly anticipated virtual roundtable will bring together leading medical exper ...

CAMARILLO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Newton Golf Company (NASDAQ: NWTG), a leader in physics-based golf shaft technology, today announced that the Company achieved its highest single-day sales total in history on Black Friday, driven by continued demand for the Fast Motion and Motion shaft families. The Company also confirmed that November 2025 is the strongest November sales month in Newton’s history. Black Friday generated the largest number of direct-to-consumer orders the Compa ...

The final event brings back the bestsellers by popular demand from Dec 2nd – Dec 7thSACRAMENTO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- After a record-smashing Black Friday, HTVRONT, the global innovator in heat press and crafting technology, is keeping the excitement alive, extending its Black Friday deals for six more days (Dec 2nd to Dec 7th) on the official website and Amazon store — offering one last chance to grab handy and innovative machines and materials at the year's lowest prices. "The Black F ...

Making HPV Tests & Quality Assessment Products Available across MexicoMISSISSAUGA, Ontario and MEXICO CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and Seegene Mexico S.A.P.I. de C.V. (Seegene Mexico), a firm focused upon transforming molecular diagnostics with innovative multiplex solutions, announce that Microbix external third-party quality assessment products (QAPs®) will be used to support the ...

EVgo Autocharge+ EVgo has surpassed five million Autocharge+ sessions. More than 300,000 customer accounts have enrolled over the last three years, representing a sixfold growth since 2022. LOS ANGELES, Dec. 03, 2025 (GLOBE NEWSWIRE) -- EVgo Inc. (NASDAQ: EVGO) (“EVgo” or the “Company”), one of the nation’s largest providers of public fast charging infrastructure for electric vehicles (EVs), has surpassed five million Autocharge+ sessions. EVgo has had sixfold growth in enrollment since 2023, with over ...

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced G50 Corp Limited (ASX: G50; OTCQX: GFTYF), a mineral exploration company, has qualified to trade on the OTCQX® Best Market. G50 Corp Limited upgraded to OTCQX from the OTCQB® Venture Market. G50 Corp Limited begins trading today on OTCQX under the symbol “GFTYF.” U.S. investors can find current financial disclosure and Real-Time ...

Core Viewpoint - BioCryst Pharmaceuticals has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed acquisition of Astria Therapeutics, indicating progress towards the merger [1][2]. Group 1: Merger Details - The termination of the waiting period satisfies one of the conditions for the merger, with BioCryst expecting the merger to close in the first quarter of 2026, pending other customary closing conditions [2]. - BioCryst has filed a registration statement with the SEC, which includes a preliminary proxy statement of Astria and a preliminary prospectus of BioCryst regarding the merger [5][6]. Group 2: Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema and other rare diseases, with a commitment to improving the lives of affected individuals [3]. - The company has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for various rare diseases [3].

TORONTO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX – V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) is pleased to announce it has awarded the contract for completion of the Iberian Belt West (IBW) Pre-Feasibility Study (PFS) to SLR Consulting Limited (formerly Wardell Armstrong) (“SLR”). The PFS will be designed to meet NI 43-101 requirements. Wardell Armstrong, which was acquired by SLR in October 2024, has been the Qualified Person (QP) responsible for the Mineral Resou ...

Core Insights - Pharvaris announced pivotal data from the RAPIDe-3 study, confirming the efficacy of deucrictibant for on-demand treatment of hereditary angioedema (HAE) attacks, with plans for marketing authorization applications in the first half of 2026 [1][7] Study Design and Results - The RAPIDe-3 study was a global Phase 3, placebo-controlled trial involving 134 participants from 24 countries, assessing the immediate-release (IR) capsule of deucrictibant (20 mg) for HAE treatment [2] - The study achieved statistical significance for the primary endpoint and all 11 secondary efficacy endpoints, making it the first on-demand HAE study compliant with the Core Outcome Set recommended in the AURORA consensus [2][3] Efficacy and Safety - Deucrictibant demonstrated a median time to onset of symptom relief of 1.28 hours, significantly faster than placebo (p<0.0001) [3][4] - All secondary efficacy endpoints were met, including a median time to End of Progression™ of 17.47 minutes and complete symptom resolution in 11.95 hours [3][4] - The safety profile of deucrictibant was well-tolerated, with no serious adverse events reported [5][9] Future Plans - Pharvaris is preparing to submit a New Drug Application (NDA) to the FDA in the first half of 2026 for deucrictibant as an on-demand treatment for HAE attacks [7][10] - An ongoing open-label extension study (RAPIDe-2 Part B) will provide additional efficacy and safety data [7] Company Overview - Pharvaris is focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated conditions, including HAE [10] - The company aims to provide therapies that combine injectable-like efficacy with the convenience of oral administration [10]

Core Insights - Target Hospitality Corp has announced a multi-year lease and services agreement known as the "Power Community Contract" to support power generation capacity expansion in Northern Nevada, expected to generate approximately $35 million in revenue over 25 months starting June 2026 [1] - The contract will enhance Target's Workforce Hospitality Solutions segment and is designed to support up to 250 individuals, showcasing the company's ability to provide comprehensive hospitality solutions [1] - The contract reflects the growing demand for power generation capacity in North America, particularly for large-scale industrial projects, and highlights Target's strategic regional presence in Northern Nevada [1] Company Overview - Target Hospitality is one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, focusing on customized solutions for various end users [1] - The company has announced over $530 million in multi-year contracts in 2025, indicating significant progress in its strategic initiatives [1] - Target's established presence in Northern Nevada was crucial for securing the Power Community Contract, allowing for minimal capital investment of approximately $8 to $10 million [1] Industry Context - The Power Community Contract underscores the increasing need for infrastructure development in remote areas to support industrial growth, particularly in mining and data center sectors [1] - The contract emphasizes the importance of high-quality workforce accommodations for the success of remote capital projects and infrastructure development [1] - Target's ability to deliver customized vertically integrated workforce accommodations positions it as a vital partner in the ongoing North American capital investment cycle [1]